| Nov 14 |
Sagimet: More Than Just A MASH Drug Development Biotech
|
| Nov 14 |
Sagimet Biosciences GAAP EPS of -$0.45
|
| Nov 14 |
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
|
| Nov 12 |
Sagimet draws buy at UBS on MASH opportunity
|
| Nov 7 |
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
|
| Oct 29 |
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
|
| Oct 18 |
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
|
| Oct 16 |
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
|
| Oct 11 |
Sagimet gains on peer-reviewed data for lead asset in MASH
|
| Oct 11 |
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
|
